Intervensi pada Stroke Non-Hemoragik
Abstract
Stroke merupakan penyebab kematian tersering ketiga di Amerika dan merupakan penyebab utama disabili-tas serius jangka panjang. Delapan puluh lima persen stroke adalah non-hemoragik yang terdiri dari 25% akibat small vessel disease(stroke lakunar), 25% akibat emboli dari jantung (stroke tromboemboli) dan sisanya akibat large vessel disease.Riset kesehatan dasar tahun 2007 mendapatkan prevalensi stroke nasional sebesar 0.8%. Stroke juga menjadi penyebab kematian paling tinggi yaitu mencapai 15.9% pada kelompok umur 45 sampai 54 tahun dan meningkat jadi 26.8% pada kelompok umur 55 sampai 64 tahun.
Stroke dikenal luas sebagai penyakit yang menimbulkan disabilitas permanen yang menyebabkan penderita kurang bah-kan tidak produktif lagi. ?al ini terjadi akibat kerusa- ?al ini terjadi akibat kerusa-kan permanen jaringan otak yang tidak tergantikan. Tetapi apakah mungkin menghindari disabilitas atau mencegah kerusakan permanen pada jaringan otak bila terjadi tromboemboli?
Downloads
Download data is not yet available.
References
Van Gijn J. Main groups of cerebral and spinal vascular disease: overview. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovas-cular disease: pathophysiology, diagnosis, and management. 1 ed. Malden: Blackwell Science; 1998:1369-1372.
Soendoro T, On behalf of RISKESDAS team. Report on result of National Basic Health Research (RISKESDAS) 2007.Jakarta: The National Institute of ?ealth Research and Develompment Ministry of ?ealth Republic of Indonesia; 2008.
Adams ?P, Jr., del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, ?igashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser R?, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American ?eart As-sociation/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Work-ing Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
?acke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Sch-neider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
Wolpert SM, Bruckmann ?, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14:3-13.
Furlan A, ?igashida R, Wechsler L, Gent M, Rowley ?, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
Fadil M, ?anafy DA, Irmalita. Percutaneous intra-arterial thrombolytic of acute ischemic stroke: initial experience. J Kardiol Indones. 2010;31:
Alberts MJ, Latchaw RE, Selman WR, Shephard T, ?adley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O’Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005;36:1597-1616.
Soendoro T, On behalf of RISKESDAS team. Report on result of National Basic Health Research (RISKESDAS) 2007.Jakarta: The National Institute of ?ealth Research and Develompment Ministry of ?ealth Republic of Indonesia; 2008.
Adams ?P, Jr., del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, ?igashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser R?, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American ?eart As-sociation/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Work-ing Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
?acke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Sch-neider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
Wolpert SM, Bruckmann ?, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14:3-13.
Furlan A, ?igashida R, Wechsler L, Gent M, Rowley ?, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
Fadil M, ?anafy DA, Irmalita. Percutaneous intra-arterial thrombolytic of acute ischemic stroke: initial experience. J Kardiol Indones. 2010;31:
Alberts MJ, Latchaw RE, Selman WR, Shephard T, ?adley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O’Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005;36:1597-1616.
Views & Downloads
Abstract views: 8324
PDF (Bahasa Indonesia) downloads: 8357
PDF (Bahasa Indonesia) downloads: 8357
How to Cite
Yuniadi, Y. (1). Intervensi pada Stroke Non-Hemoragik. Indonesian Journal of Cardiology, 31(3), 153-5. https://doi.org/10.30701/ijc.v31i3.126
Section
Editorial
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
